Further innovations include a STING-activating nanoadjuvant constructed by ionizable prodrug conjugation of a non-nucleotide agonist (MSA-2), which undergoes PEG deshielding in acidic TME to enable controlled release and potent STING activation in colorectal and triple-negative breast cancer models [75]. The gene discussed is STING1; the disease is triple-negative breast carcinoma.